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Background
a vast body of evidence has emerged, in the recent 
decades, indicating the persistence of high-risk Human 
Papillomavirus (HPV) infection as the necessary cause, 
although not sufficient, for the development of cancer 
of the uterine cervix [1-3]. The biological details that 
explained the role of HPVs in cervical cancer etiology 
described some steps (HPV infection and persistence 
over time, integration into the host genoma and overex-
pression of E6-E7 oncoproteins, growth of precancer le-
sions, progression to invasion) that can be distinguished 
and which provide a background for the secondary 
prevention of such carcinoma [4]. 
Cervical cancer is the second most common cancer in 
women, accounting for at least 250,000 deaths per year 
worldwide, and overall the disease burden attributable 
to HPV is significant, with more than 5% of all cancers 
worldwide attributed to such infections [5]. indeed, it 
is currently well documented that a significant propor-
tion of vulvo-vaginal, anal and oro-pharyngeal cancers 
among women (as well as anal, oro-pharyngeal, and 
penile cancers among men) are etiologically related to 
the same high-risk HPV types. 
in terms of prevention the burden of scientific knowl-
edge regarding Papillomavirus infection has translated 
in two main applications that will provide important 
health benefits: HPV-Dna testing and HPV-vaccine. in 
the last years molecular testing for high-risk HPV types 
become available for clinical use, thus changing the 
strategy of secondary prevention [6] and management 
of intraepithelial cervical lesions [7]. Furthermore, an 
effective screening program will be a prerequisite for 
the evaluation of vaccines effectiveness, and thus vac-
cination and cytologic screening will be complementary 
strategies. although HPV-immunization programs still 
reveal a number of unanswered questions and some 
author stressed the necessity of prudence [8, 9], they 
represents an extraordinary opportunity for primary pre-
vention against cervical cancer and other HPV-related 
pre-neoplastic/neoplastic diseases. 
Thus a global prevention program (through HPV immu-
nization integrated into cytological screening) is viewed 
as an important breakthrough in public health.
nevertheless, how to most efficiently carry out such 
global prevention of cervical cancer is still unclear. This 
issue will necessitate collaboration among gynecolo-
gists, oncologists and experts in preventive medicine, 
in immunization programs and in sexually transmitted 
diseases as well.
The HPV vaccines
Two HPV-vaccines, made both by Dna recombinant 
techniques, are commercially available so far. The 
quadrivalent vaccine (GarDaSiL™, Sanofi Pasteur 
MSD) and the bivalent vaccine (CErVariX™, GSK) 
use an expression systems based on Yeast and Baculo-
virus, respectively, and are constituted of subunits of the 
L1 viral protein, assembled into Dna-free structures 
called virus-like particles (VLPs) which are not infec-
tious, nor oncogenic. 
Both vaccines protect against HPV types 16 and 18, 
that are responsible for over 70% of the squamous and 
glandular cervical cancers [10, 11], as well as other 
genital pre-neoplastic/neoplastic diseases (vulvo-vag-
inal). Moreover, oro-pharynx neoplasias have also 
been linked to HPV infections [12, 13]. additionally, 
the quadrivalent vaccine protects also against HPV 6 
and HPV 11 infections that are associated to over 90% 
of anogenital warts and juvenile respiratory papillo-
matosis [14, 15]. 
The current indications are: prevention of premalignant 
cervical lesions and cervical cancer for both vaccine 
and, actually limited to quadrivalent vaccine, also pre-
vention of high-grade premalignant vulvo-vaginal le-
sions (Vin2/3 and Vain 2/3) and external genital warts 
(condyloma acuminata) related to vaccine types.
The goal of both prophylactic vaccines is to reduce and 
contain the incidence of HPV related disease by means 
of a potent (above the level of natural infection) and 
long-lasting humoral immune response. High level of 
type-specific igG, elicit by the vaccines, will prevent 
viral entry into the cells, thus protecting against the 
infection.
The high immunogenicity generated by the vaccines 
depend on the itself nature of VLP (which display many 
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neutralising epitopes, induce good T cell helper respons-
es for B cells, important for robust antibody and B cell 
memory responses), and is also related to the adjuvant 
employed: aaHS in quadrivalent vaccine (amorphous 
aluminum HydroxyPhosphate Sulphate) and aSO4 in 
bivalent vaccine (a combination of aluminium hydrox-
ide and monophosphoryl lipid a [MPL]). 
in order to value the efficacy and clinical benefit, the 
female populations of the clinical trials have be divided 
into three categories: 
I.	 	 per-protocol	 population	 (PP)	 included ran-
domised women:
  1. naïve to relevant vaccine HPV type through all 
vaccination protocol; 
  2. received all three vaccinations;
  3. no protocol deviation;
  4. efficacy evaluated after dose 3;
II.		 modified	 intention-to-treat	 (mITT)	 included 
randomised women:	
  1. naïve to relevant vaccine HPV type at inclu-
sion; 
  2. received at least 1 vaccination; 
  3. efficacy evaluated after dose 1;
III.	 intention-to-treat	population	(ITT)	 included all 
randomised women:
  1. all randomised women regardeless of baseline 
status; 
  2. received at least 1 vaccination; 
  3. efficacy evaluated after dose 1.
as demonstrated in phase iii randomized trials [16-19] the 
clinical efficacy of vaccines against high grade cervical in-
traepithelial neoplasias (Cin2+) is close to 100% in HPV-
naïve women (per-protocol analysis), and remains high 
also in the modified intention to treat population, but it is 
much lower in women previously exposed to vaccine-tar-
geted HPV types at the time of vaccination (intention-to-
treat). Nevertheless, the protection in ‘‘intention-to-treat’’ 
vaccinated population would be expected to increase over 
time as women in the placebo group continue to become 
infected with vaccine-targeted types of HPV. Further-
more,	 this data also highlights the prophylactic nature 
of the vaccines, that do not accelerate clearance of viral 
infections [20], nor prevent the development of Cin in 
already infected women. 
Quadrivalent vaccine has been approved by the FDa 
(US Food and Drug administration) and the EMEa 
(European Medical Evaluation agency) in 2006, and 
since then has received approval by other regulatory 
authorities in over 100 countries. The bivalent vaccine 
was approved in australia and by the EMEa in 2007, 
and in over 60 countries. The US-advisory Committee 
on immunization Practices (aCiP) and many scientific 
societies (american College of Obstetricians and Gyne-
cologists, american Cancer Society, Society of Gyne-
cologic Oncologists) recommended that the organized 
HPV vaccination programs target females 11 to 12 years 
of age, when the immunological response to vaccine is 
most effective and the HPV-seroprevalence is very low 
(i.e. ≤ 3% for HPV-16) [21]. Moreover, catch-up pro-
grams are also recommended up to 26 years old women 
irrespective of HPV status [22]. 
Ongoing studies are evaluating HPV vaccines in women 
over the age of 26. The rationale for vaccination of adult 
women is that, even though HPV peak incidence rate oc-
cur between the ages of 15 and 25, the majority of adult 
women have not been previously infected with HPV-16 
and/or HPV-18 [23]. Moreover, it should emphasize 
that low antibody levels after natural infection do not 
guarantee protection against re-infection of the same 
genotype or HPV-reactivation [24, 25], thus suggesting 
that the vast majority of women (even over 25 yrs old) 
could have benefit from vaccination. We also should 
take into account that a second peak of HPV infection 
has been reported after the menopause [26]. What is 
the significance of such peak remains to be solved: 1-
reactivation of latent infection; 2- acquisition of a new 
infection; 3- a reduced capacity to respond to infectious 
agents as a result of decline in immune function [27].
it has been established in the FUTUrE studies [28] that 
some women in the placebo-group developed disease 
despite having antibodies to the offending HPV types at 
enrollment, thus confirming that natural infection-elic-
ited antibodies may not provide complete protection to 
HPV over time. Furthermore, the conserved high local 
and systemic antibody responses in adult women (from 
26 to 55 years old) has been assessed up to 2 years 
after the administration of the first dose of bivalent vac-
cine [29], thus predicting that women above 26 years of 
age are likely to benefit from HPV vaccination if further 
exposed to HPV 16 or 18. Moreover, ad-interim results 
for quadrivalent vaccine shown high profilactic efficacy 
against disease related to HPV 6,11,16,18 in women up 
to 45 years naïve to vaccine types [30].
Cross-protection on HPV-genotypes not included into 
vaccine is strictly related to the polyclonal nature of the 
immune response to vaccination. Preventing infection 
and diseases associated with additional oncogenic geno-
types immunologically related to HPV 16 and 18 (par-
ticularly HPV 31 and 45) may provide an extra measure 
of protection. a statistically significant protective effect 
against virological and clinical end-point regarding 
HPV 31 (persistent infection and Cin2-3/aiS related 
diseases) has been reported after quadrivalent vaccine in 
naïve population  [31] and in iTT population [32]. also 
for bivalent vaccine has been reported a cross-protection 
against incident infection (with a 66 months of follow-
up) and persistent infection (in a short-term 6-months 
analysis) of HPV 31, HPV 52 and HPV-45 [19, 33]. 
indeed, the recently up-dated results from bivalent trials 
confirm the significant cross-protective efficacy against 
Cin2+ associated with non-vaccine oncogenic HPV 
types such as 31 and 33 [34]. 
although the clinical benefit for non-vaccine HPVs is not 
expected to be fully complete as observed for the vaccine 
relevant genotypes, such additional protection could in-
crease the expected reduction in cervical cancer.
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The vaccination programs
in most European countries the national public health 
authorities, through their government advisory panels, 
recommended the use of HPV-vaccines in national vac-
cination programs in order to maximize the public health 
benefit. in December 2007 the italian Health Ministry 
and the italian regions stated to offer free vaccine to all 
italian girls at 12 years old. Vaccination programs started 
over the year 2008 with the exception of one region (Ba-
silicata) where vaccination was implemented in 2007. 
in this context, vaccination should preferentially occur 
through organized programs in (multi)cohorts prior to 
sexual debut (pre HPV-exposition) or close to it. 
This setting represents the primary target population for 
HPV vaccination in italy, and allows for better stand-
ardization, a more rigorous monitoring of vaccination, 
and is likely to benefit the community nation-wide. 
This is particularly true when organized vaccination is 
compared with the vaccination on an individual basis. 
Opportunistic vaccination is based on a different set of 
considerations than those used in nation-wide programs, 
and the ultimate goal is primarily to protect and provide 
benefit to an individual woman, sometimes irrespective 
of age. Moreover, vaccines should also be offered in 
catch-up programs considering the actual official indi-
cation of the products at least to girls up to 16 years of 
age, which corresponds to the upper limit of the italian 
obligatory school and will facilitate for high coverage. 
as a matter of fact, some regions provide free access to 
vaccination not only to 12 but also to 13 years old girls 
and to women older than 13, at a discounted price.
Some issues remain unsolved as we enter the era of 
vaccination against cervical cancer and other HPV-re-
lated diseases. although vaccination has been the single 
most effective public health intervention to protect 
people against infectious diseases, it demands a capil-
lary spread, a high acceptance among the population, 
an elevated coverage of the target population and the 
certainty of sustainable economic resources over time. 
although religious or ethic reactions against vaccination 
in adolescents may be take into account (due to the fear 
that vaccine will promote early sexual activity or might 
encourage risky sexual behavior), data concerning the 
parents acceptance are reassuring [35] and mothers are 
more pragmatic than we might credit them for [36]. 
Moreover the first data regarding vaccination cover-
age one year after the start of vaccination programs in 
different italian regions show high acceptance of vac-
cination in both 12 and 13 years old age groups. Despite 
that, as for many other western countries, also in italy 
women’s knowledge about HPV infection and cervical 
cancer was remarkably poor, as only 23.3% ever heard 
of them [37]. 
The screening system 
it is critical that women (whether vaccinated or not) 
continue cytological screening. The need for continue 
screening program also for vaccinated women is related 
to the following factors: 
• all genital preinvasive/invasive lesions are not exclu-
sively generated by HPV 16 or 18;
• the rate of cross-protective benefit is still to be de-
finitively proven;
• the duration of both HPV vaccines has to be evaluat-
ed and monitored during the vaccination programs;
• the optimal vaccine benefit is demonstrated in naïve 
adolescents/young women, i.e. before they have 
naturally encountered papillomavirus.
although disparities exist in access to nationwide cyto-
logical programs and although the lack of randomized 
trials, screening with Pap-test has showed to be highly 
effective as secondary prevention in most of Western 
countries. in north america, as well as in Europe, the 
introduction of cervical screening programs has been as-
sociated with reductions in cervical cancer mortality up 
to 60% [38]. also in italy due to organized, as well as 
opportunistic, screening programs, cervical cancer mor-
tality significantly dropped from 8.6/100,000 in 1980 to 
3.7/100,000 in 2002. 
indeed, we cannot forget that even if the vaccine will 
become more and more widespread, several genera-
tions of women worldwide would still need secondary 
prevention methods because, as quoted by Bosch [39], 
“…for most living women today, screening remains 
their primary option for cervical cancer prevention”. 
nevertheless, we can anticipate that screening cyto-
logical protocols will change in the next future, (for both 
vaccinated and non-vaccinated female populations), so 
that effective introduction of HPV-vaccines will require 
an understanding of such new paradigms of cervical 
cancer prevention. 
indeed, due to the low sensitivity and low reproduc-
ibility of cervical cytology, screening strategies are 
already changing beyond the innovative wave of HPV-
vaccination. in this way we are moving from a preven-
tion model based on cytology-colposcopy-histology 
to a biomolecular model based on virologic detection 
of HPV and its molecular interactions with the human 
host [40-43]. The rationale is to use the most sensitive 
test to detect life threatening HPV-infections as up-front 
tool to identify all women at risk for HSiL, followed by 
a more specific test (Pap-test) as triage to avoid unneces-
sary referral to colposcopy. 
an increasing number of trials have been published that 
support the high sensitivity of HPV Dna testing, relative 
to cytologic evaluation for detecting high-grade cervical 
intraepithelial neoplasia. Up-to-now clinical applications 
of HPV testing are: 1-triage of women with equivocal cy-
tology results (atypical squamous cells of undetermined 
significance, aSC-US); 2-surveillance after therapy for 
cervical intraepithelial lesions; 3- as in addition to cervi-
cal cytology screening over 30 years). incidence rate of 
Cin3+ among HPV-Dna negative women suggests that 
preventive strategies in which women are screened every 
six years, are safe and effective [44]. 
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Moreover, HPV-testing (contrarily to conventional cy-
tology) will maintain its performance also in populations 
with low-HPV prevalence, as a result of vaccination. 
The need for a global prevention 
strategy
at this moment the main challenges are how to properly 
combine the two such preventive tools (primary and 
secondary prevention) and how to optimize overall costs 
of this new global strategy.
Within the setting of an organized cervical screening 
program, many mathematical predictive models dem-
onstrated that prophylactic HPV vaccination can reduce 
cervical cancer, Cin lesions and other genital HPV-re-
lated diseases [45, 46]. The costs of HPV-vaccination 
will be balanced by the savings of reduction in disease 
incidence, less diagnostic and therapeutic procedures. 
From such models (assumed 90% vaccine efficacy for at 
least 10 years and vaccine coverage in 100% of 12-year-
old girls) vaccination at 12 years of age with biennial 
screening beginning at age 24 results the most appealing 
cost-effective strategy [44, 47]. 
The rationalization of new screening strategies in low 
HPV-prevalence settings following HPV vaccination 
may allow to reduce costly screening programs: defer-
ring the age of starting screening, lengthening the time-
interval between screening rounds or modulating the 
proper timing between vaccination and screening. all 
these modulations will translate in new screening algo-
rithms for immunized women and could provide evi-
dence of cost-effectiveness of papillomavirus vaccine. 
in italy, having started mass-vaccination of the 12-yrs-
old girls during 2008, we have time enough to moni-
tor such variables that may occur over time and that 
may properly modify the future preventive guidelines 
(i.e. when the vaccinated cohort will be called by the 
screening system). Specific public programs have been 
set-up in different italian regions to monitor long-term 
effectiveness, possible adverse events and increased 
prevalence of other genotypes as result of a replacement 
phenomenon.
as for all new vaccinations some key-points need to be 
clarified because of the limitations of currently available 
data. The american Cancer Society [48] pointed out 
that the clinical impact of vaccination on cervical cancer 
will depend upon several unknown factors: 1-the degree 
of vaccination coverage; 2- the durability of protection, 
and thus the need for further boosts; 3- acceptability of 
community; 4- additive role of cross-protection. These 
issues still represents an obstacle to forecast the future 
most effective prevention strategy, although the char-
acteristics and experience of the italian public health 
system can provide monitoring of all them and properly 
modify the future guidelines and adequate adjustments 
to the ongoing vaccination programs. 
any changes in cervical cancer prevention policies 
(with or without vaccination) have to be addressed re-
garding all women at risk and, if not broadly accepted, 
could translate into higher disparities among the vari-
ous socio-cultural layers of the female population. We 
should rather avoid increasing disparities among socio-
economic groups, limiting the benefits of vaccine only 
to the higher-income subset of societies. indeed, the 
high price of both vaccines means that they are more 
available to a small proportion of the population that can 
afford to pay for them. 
This could be the scenario if vaccine uptake would be 
low in pre-teens, with a high-rate of opportunistic vac-
cine uptake among older girls (24-26 yrs old) already 
adhering to national screening recommendations. in this 
hypothetical scenario, despite high costs, we would not 
expect a significant decrease in cervical cancer mortal-
ity and morbidity. 
another contemplated scenario concerns the false sense 
of safety produced by the vaccination. Some vaccinated 
women may perceive to be fully protected from cervical 
cancer and may be less likely to participate in screening 
programs. in the United States it has been hypothesized 
that if 50% fewer vaccinated women participate in 
screening over a 5 year period following HPV vaccina-
tion [49] there would be 4 missed Cin2–3 among 1000 
women. Moreover, vaccinated women may also perceive 
to be totally protected from sexually transmitted diseases 
other than papillomavirus, potentially leading to changes 
in their sexual behaviour and increasing the frequency of 
other sexually transmitted infections. again, the italian 
public system through the organized active and free call 
for screening can circumvent this risk. 
Conclusions
a long-term and accurate monitoring system is needed: 
• to fully ascertain the population-based impact and 
public health significance of vaccination;
• to verify the economic impact for each country, 
concerning the local issues regarding the dynamic 
process of vaccination (prevalence, sexually ac-
tive population, access to health care, ecc.). it 
is reasonable [50] that the initial positive public 
health benefit (short-term analysis) will be most 
apparent for anogenital warts, targeted by low-
risk HPV 6 and 11 [51], followed by an increasing 
benefit over time for all the other HPV-related 
diseases. 
it is important to consider that all of the above men-
tioned benefits will emerge only when harmonizing the 
prevention strategies and assuring over time a clear and 
complete information to the community [52].
Considering that full impact on cervical cancer will take 
many decades to be revealed, our final recommenda-
tions about HPV-vaccination are concerning practical 
issues surrounding implementation of these vaccines in 
this moment: 
1. Set-up cost-effective preventive programs combin-
ing vaccination and screening, based on the specific 
HPV-prevalence in the corresponding geographical 
area.
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2. intensify efforts to implement organized vaccination 
programs with high-coverage among HPV-naive 
girls, possibly through multicohort programs. 
3. Provide adequate HPV type specific surveillance 
to monitor any changes in HPV type distribution 
among the general population, to assess the impact 
of vaccination.
4. Evaluate cross-protection and HPV type-replace-
ment.
5. Ensure adequate access to, and links between, vac-
cination-registries and screening-registries.
6. Verify the vaccine efficacy in men and in high-risk 
subsets of patients (HiV, immunosupressed).
although the proper way to combine primary and sec-
ondary prevention into a integrated program remains to 
define, the potential of this global strategy is to com-
plete the goal of cervical cancer eradication in the next 
decades. 
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